Powered by

GNW: Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a

Oct 16, 2020 - AWP OTS (Original Text Service)

potential first-in-class siRNA for the treatment of high cholesterol

* If approved, inclisiran will be the first and only small interfering RNA(siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1

* Cardiovascular disease (CVD) claims 3.9 million lives annually in Europe2,and 80% of high-risk patients do not reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets despite the widespread use of statins3-5

* Inclisiran provides eff...